title: New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.
authors.affiliation: Eastern Health and Monash University Eastern Health Clinical School, Melbourne, Victoria, Australia. daniel.van-langenberg@monash.edu.
authors.forename: Daniel R
authors.initials: DR
authors.lastname: van Langenberg
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016023:Integrins / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy / Q000379:methods*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D016023:Integrins; D014409:Tumor Necrosis Factor-alpha; C543529:vedolizumab; D000069285:Infliximab; D000068879:Adalimumab